QUALITY OF PATIENT’S LIFE AFTER MULTIPLE MYELOMAREGRESSION

Autor: Yu. M. Kolesnik, B. B. Samura
Jazyk: English<br />Russian<br />Ukrainian
Rok vydání: 2014
Předmět:
Zdroj: Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Iss 3, Pp 77-83 (2014)
Druh dokumentu: article
ISSN: 2409-2932
2306-8094
DOI: 10.14739/2409-2932.2014.3.33877
Popis: The aim of this study was to compare the quality of patient’s life after multiple myeloma regression in regard with demographic, clinical, psychosocial risk factors of poor prognosis, depending on the occurrence of cardiovascular events. Methods: Subjects with full or partial remission of multiple myeloma were enrolled in the study.Diagnosis and staging of multiple myeloma were defined by current clinical practice guidelines. To be achieving remission chemotherapy with MPT, MP, CVP, PAD, VMPT, VADTD, CTD, VMP was used accordingly contemporary clinical guidelines. All subjects were at full or partial remission stage at baseline. Surveys were given to multiple myeloma survivors on average who participated in the study after reaching regression and were monitored during 12 months. 95 patients were invited to complete the 36-item Short Form Health Survey (SF-36) and the Quality of Life-Cancer Survivors questionnaire (QOL-CS), and 89 patients (93.7%) responded. Standardized measures of quality of life, perceptions of the impact of myeloma, symptoms, and demographic variables were examined using linear regression modeling to identify predictors of quality of life over time.Echocardiography in B-mode was performed accordingly to Recommendation of American Society of Echocardiography on the scanner “MyLab 50” (Italy) using a transducer with a frequency of 2.5-3.5 MHz. Results: One hundred three cumulative clinical events occurred in 38 patients (42.7%). Patients who had cardiovascular events reported significantly worse psychological well-being, general health, less vitality and health-related quality of life than patients who had not cardiovascular events. Chemotherapy was associated with quality of life outcomes. Patients who were not diagnosed cardiovascular events reported better social well-being than patients who were diagnosed cardiovascular events. Improvement in life quality over a long period has not been documented previously in patients with multiple myeloma, although it is known that they experience a significant improvement in life quality soon after the completion of therapy compared with their baseline levels. The observed differences in life quality were significant only when they were measured with the QOL-CS, and not with the SF-36. This may reflect, in large part, the fact that the QOL-CS was developed specifically for use among cancer survivors, whereas the SF-36 is a generic HRQL instrument. Conclusion: The general health perceptions and vitality levels of multiple myeloma survivors with cardiovascular events remained significantly lower than those of patients without cardiovascular events.
Databáze: Directory of Open Access Journals
Externí odkaz: